Instrument Inactif

Autres langues Ceapro Inc Toronto S.E.

Actions

CZO

CA1499071076

Recherche biotechnologique et médicale

Autres langues

03/06/24	Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly
03/06/24	Aeterna Zentaris and Ceapro Complete Merger Transaction
03/06/24	Aeterna Zentaris and Ceapro Complete Merger Transaction
03/06/24	Canadian Investment Regulatory Organization Trading Halt - CZO
03/06/24	Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.
29/05/24	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
29/05/24	Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
17/05/24	Aeterna Zentaris Finalizes Some Details for Ceapro Merger
17/05/24	Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro
29/04/24	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
29/04/24	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
29/04/24	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
29/04/24	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
28/03/24	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions
28/03/24	Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris
28/03/24	Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
27/03/24	Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update
27/03/24	Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share
27/03/24	Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency
12/03/24	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12/03/24	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
26/02/24	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
26/02/24	Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co